See more : Bowim S.A. (BOW.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Cadrenal Therapeutics, Inc. Common Stock (CVKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cadrenal Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Epsilon Energy Ltd. (EPSN) Income Statement Analysis – Financial Results
- Hangzhou Anysoft Information Technology Co., Ltd. (300571.SZ) Income Statement Analysis – Financial Results
- argenx SE (ARGX.BR) Income Statement Analysis – Financial Results
- Toys”R”Us ANZ Limited (TOY.AX) Income Statement Analysis – Financial Results
- Shenzhen Colibri Technologies Co., Ltd. (002957.SZ) Income Statement Analysis – Financial Results
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 1.98K | 1.27K |
| Gross Profit | -1.98K | -1.27K |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 4.08M | 392.86K |
| General & Administrative | 3.55M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 3.55M | 2.31M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 7.63M | 2.70M |
| Cost & Expenses | 7.63M | 2.70M |
| Interest Income | 249.09K | 0.00 |
| Interest Expense | 17.10K | 107.11K |
| Depreciation & Amortization | 1.98K | 1.27K |
| EBITDA | -8.34M | -6.61M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -7.63M | -2.70M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -724.24K | -4.01M |
| Income Before Tax | -8.36M | -6.71M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 |
| Net Income | -8.36M | -6.71M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -9.63 | -8.66 |
| EPS Diluted | -9.63 | -8.66 |
| Weighted Avg Shares Out | 868.18K | 775.64K |
| Weighted Avg Shares Out (Dil) | 868.18K | 775.64K |
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
PONTE VEDRA, Fla. , Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths...
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood...
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PONTE VEDRA, Fla. , July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths...
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
PONTE VEDRA, Fla. , June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due...
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in...
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
PONTE VEDRA, Fla. , May 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots...
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
PONTE VEDRA, Fla., May 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients...
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
PONTE VEDRA, Fla. , April 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots...
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin PONTE VEDRA, Fla. , April 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and...
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
PONTE VEDRA, Fla., March 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients...
Source: https://incomestatements.info
Category: Stock Reports